Total Payments
$163,522
2024 Payments
$67,181
Companies
14
Transactions
165
Payment Breakdown by Category
Consulting$112,198 (68.6%)
Travel$23,668 (14.5%)
Other$14,217 (8.7%)
Research$8,838 (5.4%)
Food & Beverage$4,538 (2.8%)
Education$63.52 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,198 | 24 | 68.6% |
| Travel and Lodging | $23,668 | 50 | 14.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,897 | 13 | 7.3% |
| Unspecified | $8,838 | 19 | 5.4% |
| Food and Beverage | $4,538 | 53 | 2.8% |
| Honoraria | $2,320 | 1 | 1.4% |
| Education | $63.52 | 5 | 0.0% |
Payments by Type
General
$154,684
146 transactions
Research
$8,838
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $56,904 | 33 | $0 (2024) |
| Novo Nordisk AS | $19,247 | 9 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $17,269 | 32 | $0 (2024) |
| Genentech USA, Inc. | $15,883 | 22 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,363 | 4 | $0 (2020) |
| Spark Therapeutics, Inc. | $9,820 | 9 | $0 (2021) |
| BioMarin Pharmaceutical Inc. | $9,574 | 10 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $8,607 | 19 | $0 (2020) |
| F. Hoffmann-La Roche AG | $3,568 | 4 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $3,542 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,181 | 55 | GENZYME CORPORATION ($37,012) |
| 2023 | $3,738 | 5 | Novo Nordisk Inc ($2,975) |
| 2022 | $17,328 | 9 | GENZYME CORPORATION ($17,328) |
| 2021 | $7,876 | 9 | Spark Therapeutics, Inc. ($2,594) |
| 2020 | $20,808 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($12,363) |
| 2019 | $21,378 | 52 | Genentech USA, Inc. ($4,537) |
| 2018 | $16,282 | 17 | Novo Nordisk AS ($10,316) |
| 2017 | $8,931 | 4 | Novo Nordisk AS ($8,931) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $438.50 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 11/15/2024 | BioMarin Pharmaceutical Inc. | ROCTAVIAN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,128.00 | General |
| Category: Hemophilia A | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Consulting Fee | Cash or cash equivalent | $5,310.00 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | In-kind items and services | $577.26 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | Cash or cash equivalent | $254.63 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $148.08 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $110.77 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $86.19 | General |
| Category: Hematology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | Cash or cash equivalent | $13.52 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Consulting Fee | Cash or cash equivalent | $15,785.00 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $458.75 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $301.58 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $181.66 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $167.58 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | Cash or cash equivalent | $60.85 | General |
| Category: Hematology | ||||||
| 10/05/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Hematology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $316.63 | Research |
| Study: ATHN 7 • Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Consulting Fee | Cash or cash equivalent | $15,785.00 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $704.98 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | In-kind items and services | $522.47 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $166.76 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Hematology | ||||||
| 09/28/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | Cash or cash equivalent | $18.90 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ATHN 7 | F. Hoffmann-La Roche AG | $3,568 | 4 |
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV00 | BIOVERATIV THERAPEUTICS INC. | $2,002 | 5 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $1,149 | 3 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A | GENZYME CORPORATION | $1,000 | 3 |
| Retrospective chart review of hemophilia A patients with inhibitors treated with rFVIIIFc for ITI | BIOVERATIV THERAPEUTICS INC. | $648.26 | 2 |
| BIVV001: The First Investigational Factor VIII (FVIII) Therapy to Break Through the Von Willebrand Factor (VWF) Ceiling, with Potential for More Optimal, Extended Protection in Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $265.00 | 1 |
| BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $205.70 | 1 |
About Dr. Janice Staber, M.D
Dr. Janice Staber, M.D is a Pediatrics healthcare provider based in Iowa City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013126705.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Janice Staber, M.D has received a total of $163,522 in payments from pharmaceutical and medical device companies, with $67,181 received in 2024. These payments were reported across 165 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($112,198).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology
- Location Iowa City, IA
- Active Since 05/21/2007
- Last Updated 01/07/2011
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1013126705
Products in Payments
- ALTUVIIIO (Biological) $34,262
- Hemlibra (Biological) $10,189
- ROCTAVIAN (Drug) $9,574
- HEMLIBRA (Biological) $9,262
- Jivi (Drug) $5,897
- NO PRODUCT DISCUSSED (Drug) $3,542
- NovoSeven (Biological) $2,975
- BIVV001 (Drug) $2,871
- Idelvion (Biological) $2,342
- ELOCTATE (Drug) $1,314
- ELOCTATE (Biological) $720.70
- Non-Covered (Drug) $64.75
- BENEFIX (Biological) $35.90
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Iowa City
Patrick Mcnamara, Mb Bch Bao Msc, MB BCH BAO MSC
Pediatrics — Payments: $27,189
Pediatrics $27,189
Yasemen Eroglu, Md, MD
Pediatrics — Payments: $11,372
Pediatrics $11,372
Dr. Kamel Shibbani
Pediatrics — Payments: $5,218
Pediatrics $5,218
Dr. Katie Larson Ode, M.d, M.D
Pediatrics — Payments: $4,691
Pediatrics $4,691
David Dickens, Md, MD
Pediatrics — Payments: $3,743
Pediatrics $3,743
Dr. James Owens, M.d, M.D
Pediatrics — Payments: $2,302
Pediatrics $2,302